Keyword: Bristol-Myers Squibb

city view

JPM Monday roundup

Well, let’s start with the obvious, a pattern that has been set for a good few years now: There were no M&A deals.
Bristol-Myers Squibb

32. Reblozyl

Bristol-Myers and Acceleron are also seeking approval in myelodysplastic syndromes, a group of cancers in which immature blood cells in the bone marrow don’t fully develop and become healthy blood cells. If Reblozyl nabs a second nod, analysts figure it could hit $2 billion in yearly sales.

6. Opdivo

2019 was something of an annus horribilis when it came to trying to find new therapies for aggressive brain cancer glioblastoma multiforme, and one of the biggest disappointments came from the failure of an immuno-oncology approach to the disease.
Fail sign

2019’s top 15 clinical trial flops (and a flip-flop)

This year’s top 15 list has been drawn up to include trials whose failure we judge to have had material consequences on their sponsors and the patients for whom the drugs are being developed. The catalog includes multiple trials for aggressive brain cancer, Alzheimer’s disease, nonalcoholic steatohepatitis and heart disease.